Advertisement
EBS vs XERS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and XERS is a StrongBuy.
Momentum Indicator for EBS turns negative, indicating new downward trend
EBS saw its Momentum Indicator move below the 0 level on October 19, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 80 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for EBS moved out of overbought territory on September 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Moving Average Convergence Divergence Histogram (MACD) for EBS turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
EBS broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for EBS crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where EBS advanced for three days, in 208 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 145 of 177 cases where EBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.936) is normal, around the industry mean (10.407). P/E Ratio (-1.832) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.493) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. EBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Momentum Indicator for XERS turns positive, indicating new upward trend
XERS saw its Momentum Indicator move above the 0 level on September 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 74 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for XERS just turned positive on September 21, 2026. Looking at past instances where XERS's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.
XERS moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for XERS crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +7.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where XERS advanced for three days, in 220 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 191 of 232 cases where XERS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for XERS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 38 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
XERS broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XERS's P/B Ratio (-203.411) is very low in comparison to the industry average of (10.407). P/E Ratio (-108.600) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (4.196) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 23 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
EBS | XERS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 44 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 23 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 75 | 36 | |
P/E GROWTH RATING 1..100 | 98 | 99 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XERS's Valuation (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for EBS (41) in the Biotechnology industry. This means that XERS’s stock grew somewhat faster than EBS’s over the last 12 months.
XERS's Profit vs Risk Rating (23) in the Pharmaceuticals Major industry is significantly better than the same rating for EBS (100) in the Biotechnology industry. This means that XERS’s stock grew significantly faster than EBS’s over the last 12 months.
EBS's SMR Rating (97) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to XERS’s over the last 12 months.
XERS's Price Growth Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for EBS (75) in the Biotechnology industry. This means that XERS’s stock grew somewhat faster than EBS’s over the last 12 months.
EBS's P/E Growth Rating (98) in the Biotechnology industry is in the same range as XERS (99) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to XERS’s over the last 12 months.
| EBS | XERS | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 89% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 90% | 3 days ago 89% |
| MACD ODDS (%) | 1 day ago 85% | 3 days ago 86% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 86% |
| Advances ODDS (%) | 25 days ago 79% | 4 days ago 86% |
| Declines ODDS (%) | 3 days ago 86% | 10 days ago 77% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 71% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EBS’s FA Score shows that 0 FA rating(s) are green while XERS’s FA Score has 2 green FA rating(s).
- EBS’s FA Score: 0 green, 5 red.
- XERS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EBS’s TA Score shows that 4 TA indicator(s) are bullish while XERS’s TA Score has 6 bullish TA indicator(s).
- EBS’s TA Score: 4 bullish, 5 bearish.
- XERS’s TA Score: 6 bullish, 4 bearish.
Price Growth
EBS (@Pharmaceuticals: Generic) experienced а -13.23% price change this week, while XERS (@Pharmaceuticals: Generic) price change was +7.85% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.51%. For the same industry, the average monthly price growth was -10.60%, and the average quarterly price growth was +7.98%.
Reported Earning Dates
EBS is expected to report earnings on Nov 02, 2026.
XERS is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.51% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
EBS and
Correlation & Price change
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.
| Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
|---|---|---|---|---|
| EBS | 100% | +0.48% | ||
| SIGA - EBS | 40% Loosely correlated | +0.96% | ||
| COLL - EBS | 40% Loosely correlated | +2.55% | ||
| AMPH - EBS | 37% Loosely correlated | -0.61% | ||
| XERS - EBS | 33% Loosely correlated | +0.70% | ||
| VTRS - EBS | 32% Poorly correlated | +0.16% | ||
More | ||||
XERS and
Correlation & Price change
A.I.dvisor indicates that over the last year, XERS has been loosely correlated with MIRM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then MIRM could also see price increases.
| Ticker / NAME | Correlation To XERS | 1D Price Change % | ||
|---|---|---|---|---|
| XERS | 100% | +0.70% | ||
| MIRM - XERS | 45% Loosely correlated | -0.41% | ||
| KROS - XERS | 38% Loosely correlated | +1.52% | ||
| AXON - XERS | 37% Loosely correlated | +2.98% | ||
| REPL - XERS | 36% Loosely correlated | +2.30% | ||
| BNTC - XERS | 36% Loosely correlated | +3.76% | ||
More | ||||